Detalles de la búsqueda
1.
The evolving landscape of tissue-agnostic therapies in precision oncology.
CA Cancer J Clin
; 2024 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38814103
2.
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
N Engl J Med
; 386(10): 942-950, 2022 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35263519
3.
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 25(5): 626-635, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38697156
4.
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
Breast Cancer Res
; 26(1): 36, 2024 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38439079
5.
Revolutionizing cancer drug development: Harnessing the potential of basket trials.
Cancer
; 130(2): 186-200, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37934000
6.
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.
Br J Cancer
; 130(7): 1131-1140, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38287179
7.
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
Breast Cancer Res Treat
; 204(1): 123-132, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38019444
8.
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Breast Cancer Res
; 25(1): 67, 2023 06 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37308971
9.
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours.
Br J Cancer
; 128(10): 1906-1915, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36871042
10.
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Br J Cancer
; 128(2): 255-265, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36482193
11.
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Future Oncol
; 19(34): 2277-2289, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37746835
12.
Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.
Oncologist
; 27(3): 175-182, 2022 03 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35274716
13.
A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.
BMC Cancer
; 22(1): 502, 2022 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35524219
14.
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
Lancet Oncol
; 22(9): 1290-1300, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34339623
15.
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Br J Cancer
; 125(5): 679-686, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34158598
16.
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
Oncologist
; 26(2): e261-e269, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33191588
17.
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.
Oncologist
; 26(11): 925-e1918, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34288257
18.
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Gynecol Oncol
; 163(3): 473-480, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34627611
19.
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol
; 163(3): 490-497, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34602290
20.
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
Cancer
; 126(11): 2597-2606, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32208524